CRINETICS PHARMACEUTICALS INC. - COMMON STOCK

Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer

01 Mar 2022 08:00:18 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter into Exclusive Licensing Agreement for the Development and Commercialization of Paltusotine in Japan

28 Feb 2022 06:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference

09 Feb 2022 07:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Feb 2022 16:42:26 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference

12 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.

05 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

18 Nov 2021 08:00:01 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress

08 Nov 2021 08:00:03 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

05 Nov 2021 08:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

25 Oct 2021 16:01:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

21 Oct 2021 08:22:33 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

20 Oct 2021 16:01:37 By Nasdaq GlobeNewswire

Radionetics Oncology Emerges from Crinetics Pharmaceuticals with a Platform and Deep Pipeline of Nonpeptide Targeted Radiopharmaceutical Drug Candidates for Precision Oncology

18 Oct 2021 16:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Unveil its Parathyroid Hormone Receptor Antagonist Program at the American Society for Bone and Mineral Research Annual Meeting

27 Sep 2021 07:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals’ Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study

15 Sep 2021 16:01:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in September Investor Conferences

07 Sep 2021 07:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Officer

02 Sep 2021 07:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

10 Aug 2021 16:02:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals’ Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study

10 Aug 2021 16:01:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners

29 Jul 2021 07:30:00 By Nasdaq GlobeNewswire